Myopathic rheumatic diseases (polymyositis, dermatomyositis, inclusion body myositis)
David Fernandez, MD, PhD
Hospital for Special Surgery
New York, NY, United States
Disclosure information not submitted.
Julie Paik, MD, MHS
Johns Hopkins University
Baltimore, MD, United States
Disclosure(s): Alexion: Grant/Research Support (Ongoing); Guidepoint: Consultant (Ongoing); Priovant: Grant/Research Support (Ongoing)
The idiopathic inflammatory myopathies (IIMs) are associated with a large and growing number of autoantibodies. These antibodies have been shown to be helpful for improving patient diagnosis and prognosis. These tests are becoming more widely available, and a profusion of methods and assays to detect these autoantibodies have been developed. However, these technologies often differ in their performance characteristics. Clinicians are required to know how to interpret these relatively new serological tests, such as when to suspect false-positive or -negative results, how to interpret if more than one antibody is positive, and differences between different laboratories and techniques. This session will discuss different autoantibody detection systems and how the interpretation of autoantibody results may differ based on how the testing is performed. Additionally, it will highlight novel insights that these tests can provide to aid in interpretation of muscle biopsy specimens.
Speaker: Sarah Tansley, PhD; BSc; MBChB – University of Bath
Speaker: Christopher Mecoli, MD – Johns Hopkins University
Speaker: Tahseen Mozaffar, MD (he/him/his) – The University of California, Irvine